NYXH

NYXH

USD

Nyxoah SA Ordinary Shares

$6.100+0.080 (1.329%)

即時價格

Healthcare
Medical Instruments & Supplies
比利時

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$6.020

最高

$6.200

最低

$6.012

交易量

0.01M

公司基本面

市值

230.2M

行業

Medical Instruments & Supplies

國家

Belgium

交易統計

平均交易量

0.13M

交易所

NGM

貨幣

USD

52週範圍

最低 $5.55當前 $6.100最高 $12.21

相關新聞

PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

查看更多
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

查看更多
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
Analyst Upgrades

Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14

Stifel analyst Jonathan Block maintains Nyxoah with a Buy and lowers the price target from $15 to $14.

查看更多
Stifel Maintains Buy on Nyxoah, Lowers Price Target to $14
GlobeNewswire

Conditional Issuance of Shares

INSIDE INFORMATIONREGULATED INFORMATION Conditional Issuance of Shares Mont-Saint-Guibert, Belgium – April 16, 2025, 8:00 am CET / 2:00 am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"),

查看更多
Conditional Issuance of Shares
PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH

Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). Such investors are advised to ...

查看更多
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH
Analyst Upgrades

HC Wainwright & Co. Reiterates Buy on Nyxoah, Maintains $15 Price Target

HC Wainwright & Co. analyst Edward White reiterates Nyxoah with a Buy and maintains $15 price target.

GlobeNewswire

Nyxoah Provides Update on FDA Approvable Letter for Genio System

Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET –